Ishami Mpuzamahanga

Ku ya 22 Mutarama 2025, "Nature Medicine" yasohoye ibyavuye muri Akeso ku giti cyayo yakoze antibody ya PD-1/CTLA-4 bispecific cadonilimab ivanze na oxaliplatin na capecitabine mu rwego rwa mbere rwo kuvura indwara zidakira zishobora kwanduzwa mu gace runaka cyangwa ziterwa n'imiti yo mu gifu cyangwa mu gifu...Soma byinshi»

Ku ya 8 Mutarama 2025, Ikigo cy’Igihugu gishinzwe Ibikoresho by’Ubuvuzi mu Bushinwa (NMPA) cyemeje PADCEVTM (enfortumab vedotin) hamwe na KEYTRUDA (pembrolizumab) ku barwayi bakuru bafite kanseri y’umura iteye imbere cyangwa ikwirakwira mu maraso (la/mUC). Kwemeza kwa NMPA kwa enfortumab vedotin mu gukamura...Soma byinshi»

Ku ya 17 Gashyantare 2025, Innovent Biologics yatangaje ko poroteyine yayo ya mbere mu cyiciro cya PD-1/IL-2α-bias bispecific antibody fusion, IBI363, yahawe izina ryayo rya kabiri rya Fast Track Designation (FTD) ritangwa n'Ikigo gishinzwe Ibiribwa n'Imiti muri Amerika (FDA). Iri zina rikoreshwa mu kuvura indwara zidakira, ...Soma byinshi»

Ku ya 16 Mutarama 2025, IMPACT yatangaje ko Senaparib Capsules (派舒宁®) yahawe uburenganzira bwo kwamamaza mu Bushinwa n'Ikigo cy'Igihugu gishinzwe Ibikoresho by'Ubuvuzi (NMPA) nk'uburyo bwo kuvura abarwayi bakuru bafite epithelial ihanitse (FIGO Stages III na IV) yo mu rwego rwo hejuru ...Soma byinshi»

Ku ya 7 Gashyantare 2025, Sichuan Kelun-Biotech Biopharmaceutical yatangaje ko Ikigo cy’Igihugu gishinzwe Ibikoresho by’Ubuvuzi (National Medical Products Agency) cyemeye inshinge za Cetuximab N01 mu kuvura kanseri y’inkondo y’umura (mCRC) mu Bushinwa. Iyi nyigo ishingiye ku bushakashatsi bwakozwe mu cyiciro cya gatatu cy’ubuvuzi...Soma byinshi»

Ku ya 10 Gashyantare 2025, CARsgen Therapeutics yatangaje ko umuntu wa mbere wavuwe hakoreshejwe uburyo bwa BCMA CAR-T bukoresha allogeneic bwakorewe kuri platform ya THANK-u Plus™, yagize igisubizo cyuzuye (sCR) n'indwara nke zisigara (MRD) mu isuzuma ryakozwe ku munsi wa 28. Yakorewe mu nzu...Soma byinshi»

Ku ya 29 Mutarama 2025, itsinda ry’abashakashatsi b’Abashinwa ryasohoye inkuru ifite umutwe ugira uti “Neoadjuvant pyrotinib na trastuzumab muri kanseri y’ibere ya HER2 idafite igisubizo hakiri kare (NeoPaTHer): imikorere, umutekano, n’isesengura ry’ibipimo by’ubushakashatsi bw’ubushakashatsi bw’ubushakashatsi bw’ubushakashatsi bw’ibizamini byinshi” muri ...Soma byinshi»

Ku ya 26 Mutarama 2025, Ikigo gishinzwe Isuzuma ry'Imiti (CDE) cy'Ikigo cy'Igihugu cy'Ubushinwa gishinzwe Ibikoresho by'Ubuvuzi cyatangaje ko inshinge za LM-108 zigenewe gushyirwa mu buvuzi bugezweho ku bibyimba bikomeye bifite imirasire idahindagurika (MSI-H) cyangwa inenge zo gusana zidahuye (dMMR) ku...Soma byinshi»

Ku itariki ya 20 Mutarama, Ikigo cy’Igihugu gishinzwe Ibikoresho by’Ubuvuzi (NMPA) cyemeye uburyo bushya bwo kuvura indwara ya monoclonal antibody tagitanlimab (yahoze ari KL-A167) ya cisplatin na gemcitabine mu kuvura abarwayi ba kanseri yo mu nda isubira cyangwa ikwirakwira mu miyoboro y’amazi (NPC). ...Soma byinshi»

Ku ya 16 Mutarama 2025, Ikigo cy’Igihugu gishinzwe Ibikoresho by’Ubuvuzi mu Bushinwa (NMPA) cyemeje Porogaramu Nshya y’Imiti ya Limertinib (NDA) mu kuvura abarwayi bakuru bafite kanseri y’ibihaha idahinduka cyangwa isanzwe ya EGFR T790M (NSCLC). Ku bijyanye na Limertinib Limertinib ...Soma byinshi»

Ku ya 8 Mutarama, Ikigo gishinzwe gusuzuma imiti (CDE) cy’Ikigo cy’Igihugu gishinzwe Ibikoresho by’Ubuvuzi mu Bushinwa (NMPA) cyahaye Icyitegererezo cyo Gukoresha Uburyo bwo Kuvura (BTD) cya IBI343, umuti ushobora kuba mwiza cyane wo kurwanya CLDN18.2 ADC, nk'umuti umwe wo kuvura CLDN18.2-positive advanced pancr...Soma byinshi»

Ku ya 8 Mutarama 2025, 9MW2821 yahawe inyito yo kuvura indwara ya Breakthrough Therapy (BTD) n'Ikigo gishinzwe gusuzuma imiti (CDE) cy'Ikigo cy'Igihugu gishinzwe Ibikoresho by'Ubuvuzi (NMPA) mu Bushinwa. 9MW2821 itangwa hamwe na toripalimab, antibody ya monoclonal anti-PD-1, kugira ngo ivurwe mu buryo butari ubwa mbere, budafite ingaruka ku buvuzi...Soma byinshi»